UY35419A - Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina - Google Patents

Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina

Info

Publication number
UY35419A
UY35419A UY0001035419A UY35419A UY35419A UY 35419 A UY35419 A UY 35419A UY 0001035419 A UY0001035419 A UY 0001035419A UY 35419 A UY35419 A UY 35419A UY 35419 A UY35419 A UY 35419A
Authority
UY
Uruguay
Prior art keywords
kinasa
pirrolo
piridine
cdk9 inhibitors
compounds
Prior art date
Application number
UY0001035419A
Other languages
English (en)
Inventor
Lai Chunqiu
Tao Zhi-Fu
Song Xiaohong
Souers Andrew
Tong Yunsong
Bruncko Milan
Richard F Clark
Michael L Curtin
Alan S Florjancic
Robin R Frey
Gong Jianchun
Ji Zhiqin
Mastracchio Anthony
Michaelides Michael
Miyashiro Juliem
Keith W Woods
Zhu Guidong
Penning Thomas
Goswami Rajeev
Iquturi Omprakash Reddy
Dabbeeru Madhu Babu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY35419A publication Critical patent/UY35419A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Compuestos de fórmula I: donde R1, R2, R3, y R4 tienen cualquiera de los valores que se definen para ellos en la memoria descriptiva, y sales aceptables farmacéuticamente de los mismos. Los compuestos se pueden usar como agentes en el tratamiento de enfermedades, entre las que se inclyue el cáncer. También se proveen composiciones farmacéuticas que comprenden uno o más compuestos de fórmula I.
UY0001035419A 2013-03-14 2014-03-13 Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina UY35419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
INDE07452013 2013-03-14
US201361904842P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
UY35419A true UY35419A (es) 2014-10-31

Family

ID=51529934

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035419A UY35419A (es) 2013-03-14 2014-03-13 Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina

Country Status (4)

Country Link
US (1) US9073922B2 (es)
TW (2) TW201444836A (es)
UY (1) UY35419A (es)
WO (2) WO2014139328A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943100C (en) 2014-03-24 2017-04-04 Hao Wu Quinoline derivatives as smo inhibitors
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
BR122019013677B1 (pt) 2015-06-29 2024-01-02 Astrazeneca Ab Compostos derivados de amida policíclica como inibidores de cdk9, composição e seus usos
JP2019500368A (ja) 2015-12-17 2019-01-10 ギリアード サイエンシーズ， インコーポレイテッド Ｔａｎｋ結合キナーゼ阻害剤化合物
HUE063042T2 (hu) 2016-04-15 2023-12-28 Blueprint Medicines Corp Az aktivin receptorszerû kináz inhibitorai
US11266640B2 (en) * 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
KR20230137889A (ko) 2020-12-18 2023-10-05 암피스타 테라퓨틱스 엘티디 표적화된 단백질 분해를 위한 신규의 2기능성 분자

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
MXPA02006338A (es) * 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
AR050365A1 (es) 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
BRPI0620341A2 (pt) * 2005-12-23 2011-11-08 Smithkline Beecham Corparation azaindóis inibidores de cinases aurora
AR062928A1 (es) * 2006-09-22 2008-12-17 Glaxo Group Ltd Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080188524A1 (en) 2006-10-25 2008-08-07 Martin Augustin Methods of treating pain
US20100093776A1 (en) * 2006-12-22 2010-04-15 Novartis Ag Organic Compounds and Their Uses
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
KR20100105802A (ko) 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
ATE510827T1 (de) 2007-10-12 2011-06-15 Ingenium Pharmaceuticals Gmbh Inhibitoren von proteinkinasen
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
US20110201599A1 (en) * 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
EP2331547B1 (en) 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof

Also Published As

Publication number Publication date
TW201444836A (zh) 2014-12-01
US9073922B2 (en) 2015-07-07
WO2014151444A1 (en) 2014-09-25
US20140275027A1 (en) 2014-09-18
WO2014139328A1 (en) 2014-09-18
TW201446763A (zh) 2014-12-16

Similar Documents

Publication Publication Date Title
UY39630A (es) Inhibidores de bromodominios
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CR20160035A (es) Inhibidores de bromodominios
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY37205A (es) Inhibidores de bromodominios
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
CR20150045A (es) Inhibidores de hepatitis c
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20150250A (es) Nuevos derivados de piridina
CR20150447A (es) Nuevos derivados de pirazol
PE20151979A1 (es) Compuestos quimicos
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204